The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
PD‐L1 co‐stimulation contributes to ligand‐induced T cell receptor down‐modulation on CD8 + T cells
Open accessAbstract
T cell receptor (TCR) down-modulation after antigen presentation is a fundamental process that regulates TCR signal transduction. Current understanding of this process is that intrinsic TCR/CD28 signal transduction leads to TCR down-modulation. Here, we show that the interaction between programmed cell death 1 ligand 1 (PD-L1) on dendritic cells (DCs) and programmed death 1 (PD-1) on CD8 T cells contributes to ligand-induced TCR down-modulation. We provide evidence that this occurs via Casitas B-lymphoma (Cbl)-b E3 ubiquitin ligase up-regulation in CD8 T cells. Interference with PD-L1/PD-1 signalling markedly inhibits TCR down-modulation leading to hyper-activated, proliferative CD8 T cells as assessed in vitro and in vivo in an arthritis model. PD-L1 silencing accelerates anti-tumour immune responses and strongly potentiates DC anti-tumour capacities, when combined with mitogen-activated kinase (MAPK) modulators that promote DC activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Self-citationWherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 2×
“590 are other pathways that inhibit effector T cell activities without modifying TCR levels (Barber et al, 2006; Choi & Schwartz, 2007; Wherry, 2011).”
BackgroundRestoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Sharpe, A. H., Wherry, E. J., Ahmed, R., & Freeman, G. J. (2007) · Nature Immunology · doi:10.1038/ni1443 · Cited by 1,528
Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246
Serial triggering of many T-cell receptors by a few peptide–MHC complexes
Valitutti, S., Müller, S., Cella, M., Padovan, E., & Lanzavecchia, A. (1995) · Nature · doi:10.1038/375148a0 · Cited by 1,128
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018
Sheppard, K.-A., Fitz, L. J., Lee, J. M., Benander, C., George, J. A., Wooters, J., Qiu, Y., Jussif, J. M., Carter, L. L., Wood, C. R., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.083 · Cited by 791
Cited by
Clinical use of lentiviral vectors
Milone, M. C., & O’Doherty, U. (2018) · Leukemia · doi:10.1038/s41375-018-0106-0 · Cited by 930
“stimulatory signals on dendritic cells to further enhance their efficacy [92, 93].”
BackgroundHodi, F. S., Hwu, W.-J., Kefford, R., Weber, J. S., Daud, A., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Gangadhar, T. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0391 · Cited by 734
Extracellular vesicles in immunomodulation and tumor progression
Marar, C., Starich, B., & Wirtz, D. (2021) · Nature Immunology · doi:10.1038/s41590-021-00899-0 · Cited by 584
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Xu-Monette, Z. Y., Zhou, J., & Young, K. H. (2018) · Blood · doi:10.1182/blood-2017-07-740993 · Cited by 433
PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
Wu, Y., Chen, W., Xu, Z. P., & Gu, W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02022 · Cited by 419
Saeidi, A., Zandi, K., Cheok, Y. Y., Saeidi, H., Wong, W. F., Lee, C. Y. Q., Cheong, H. C., Yong, Y. K., Larsson, M., & Shankar, E. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02569 · Cited by 350
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches
Liu, F., Chen, J., Li, K., Li, H., Zhu, Y., Zhai, Y., Lu, B., Fan, Y., Liu, Z., Chen, X., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02046-3 · Cited by 326
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
Beldi-Ferchiou, A., Lambert, M., Dogniaux, S., Vély, F., Vivier, E., Olive, D., Dupuy, S., Levasseur, F., Zucman, D., Lebbé, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12150 · Cited by 312
PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
Gato-Cañas, M., Zuazo, M., Arasanz, H., Ibañez-Vea, M., Lorenzo, L., Fernandez-Hinojal, G., Vera, R., Smerdou, C., Martisova, E., Arozarena, I., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.075 · Cited by 312
Self-citationThe intracellular signalosome of PD-L1 in cancer cells
Escors, D., Gato-Cañas, M., Zuazo, M., Arasanz, H., García-Granda, M. J., Vera, R., & Kochan, G. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0022-9 · Cited by 292
Self-citationPD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Xu-Monette, Z. Y., Zhang, M., Li, J., & Young, K. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01597 · Cited by 288
PD1 signal transduction pathways in T cells
Arasanz, H., Gato-Cañas, M., Zuazo, M., Ibañez-Vea, M., Breckpot, K., Kochan, G., & Escors, D. (2017) · Oncotarget · doi:10.18632/oncotarget.17232 · Cited by 270
Self-citationA comprehensive review of immune checkpoint inhibitors for cancer treatment
Arafat Hossain, M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 178
Friedman, J., Moore, E. C., Zolkind, P., Robbins, Y., Clavijo, P. E., Sun, L., Greene, S., Morisada, M. V., Mydlarz, W. K., Schmitt, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2209 · Cited by 88
PD-1 coinhibitory signals: the link between pathogenesis and protection
Kulpa, D. A., Lawani, M., Cooper, A., Peretz, Y., Ahlers, J., & Sékaly, R.-P. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.02.002 · Cited by 70
Metadata
- Authors
- Karwacz, K., Bricogne, C., MacDonald, D., Arce, F., Bennett, C. L., Collins, M., & Escors, D.
- Venue
- EMBO Molecular Medicine
- Published
- 2011-08-10
- Volume
- 3
- Issue
- 10
- Pages
- 581-592
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2097514222
- Cited by
- 265
- References
- 42
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.